OptimizeRx (NASDAQ:OPRX) Coverage Initiated by Analysts at Stephens

Research analysts at Stephens assumed coverage on shares of OptimizeRx (NASDAQ:OPRX) in a research note issued on Friday,Briefing.com Automated Import reports. The brokerage set an “equal weight” rating and a $5.50 price target on the stock. Stephens’ target price would indicate a potential upside of 15.79% from the stock’s current price.

A number of other research analysts also recently weighed in on OPRX. Stifel Nicolaus decreased their target price on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Roth Mkm reiterated a “buy” rating and set a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Barclays decreased their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th. Finally, Royal Bank of Canada dropped their price objective on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, OptimizeRx presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.71.

OptimizeRx Trading Down 0.6 %

NASDAQ OPRX opened at $4.75 on Friday. The stock has a market capitalization of $87.50 million, a price-to-earnings ratio of -3.57 and a beta of 1.34. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $16.65. The stock’s 50 day moving average price is $5.41 and its two-hundred day moving average price is $7.87. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23.

Insider Buying and Selling

In related news, CEO William J. Febbo purchased 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the purchase, the chief executive officer now owns 601,253 shares in the company, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 6.10% of the stock is owned by insiders.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors have recently made changes to their positions in OPRX. BNP Paribas Financial Markets lifted its holdings in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the last quarter. Connors Investor Services Inc. lifted its holdings in shares of OptimizeRx by 15.1% during the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after buying an additional 2,500 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of OptimizeRx in the second quarter valued at about $25,000. Rhumbline Advisers grew its stake in shares of OptimizeRx by 9.2% in the second quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after acquiring an additional 2,658 shares in the last quarter. Finally, Greenwood Capital Associates LLC increased its position in OptimizeRx by 8.0% during the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock worth $520,000 after acquiring an additional 4,999 shares during the period. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.